<DOC>
	<DOC>NCT01803477</DOC>
	<brief_summary>The purpose of this study is to determine if the new vehicle formulations containing ingenol mebutate are as safe and effective as Picato速 gel 0.05% (it's current vehicle formulation) when applied to AK lesions on the forearm for two consecutive days.</brief_summary>
	<brief_title>Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm</brief_title>
	<detailed_description>This study will be run in 2 parts. The first part involves applying escalating concentrations of the new vehicle formulations containing ingenol mebutate to AKs on the forearms. Reactions and safety will be compared to Picato速 (a registered and marketed ingenol mebutate gel) to ascertain if the new vehicle formulations are at least as safe and effective as Picato速 . The purpose of part 2 is to select the concentration in the "new formulation" that produces this same, if not better response, as Picato速 and with a similar or better safety profile.</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis, Actinic</mesh_term>
	<criteria>Must be male or female and at least 18 years of age. Female patients must be of nonchildbearing potential or if of childbearing potential then negative serum and urine pregnancy test and using effective contraception. Ability to provide informed consent. location of the selected treatment area within 5cm of an incompletely healed wound or within 5cm of a suspected basal cell carcinoma or squamous cell carcinoma undergone Cosmetic or therapeutic procedures within 2cm of the selected treatment area in the 2 weeks prior to the treatment visit presence of sunburn within the selected treatment areas use of acidcontaining therapeutic products within 2cm of the selected treatment area in the 2 weeks prior to the treatment visit previous enrolment in this clinical trial prior treatment with ingenol mebutate on the forearms use of topical moisturisers/creams/lotions, artificial tanners or topical steroids within 2cm of the selected treatment areas in the 2 weeks prior to the treatment visit treatment with immunomodulators, or interferon/interferon inducers or systemic medications that suppress the immune system within 4 weeks of the treatment visit treatment with 5FU, imiquimod, diclofenac,or photodynamic therapy within 2 cm of the treatment area in the 8 weeks prior to the treatment visit use of systemic retinoids those who are currently participating in any other clinical trial females who are pregnant or are breastfeeding those known or suspected or not being able to comply with the requirements of the protocol or provide consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>